GSK Management
Management criteria checks 2/4
GSK's CEO is Emma Walmsley, appointed in Apr 2017, has a tenure of 7.67 years. total yearly compensation is £12.72M, comprised of 10.3% salary and 89.7% bonuses, including company stock and options. directly owns 0.04% of the company’s shares, worth €26.01M. The average tenure of the management team and the board of directors is 6 years and 3.3 years respectively.
Key information
Emma Walmsley
Chief executive officer
UK£12.7m
Total compensation
CEO salary percentage | 10.3% |
CEO tenure | 7.7yrs |
CEO ownership | 0.04% |
Management average tenure | 6yrs |
Board average tenure | 3.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | UK£3b |
Jun 30 2024 | n/a | n/a | UK£4b |
Mar 31 2024 | n/a | n/a | UK£4b |
Dec 31 2023 | UK£13m | UK£1m | UK£5b |
Sep 30 2023 | n/a | n/a | UK£6b |
Jun 30 2023 | n/a | n/a | UK£5b |
Mar 31 2023 | n/a | n/a | UK£4b |
Dec 31 2022 | UK£8m | UK£1m | UK£4b |
Sep 30 2022 | n/a | n/a | UK£3b |
Jun 30 2022 | n/a | n/a | UK£4b |
Mar 31 2022 | n/a | n/a | UK£4b |
Dec 31 2021 | UK£8m | UK£1m | UK£3b |
Sep 30 2021 | n/a | n/a | UK£4b |
Jun 30 2021 | n/a | n/a | UK£4b |
Mar 31 2021 | n/a | n/a | UK£5b |
Dec 31 2020 | UK£7m | UK£1m | UK£5b |
Sep 30 2020 | n/a | n/a | UK£6b |
Jun 30 2020 | n/a | n/a | UK£7b |
Mar 31 2020 | n/a | n/a | UK£5b |
Dec 31 2019 | UK£8m | UK£1m | UK£5b |
Sep 30 2019 | n/a | n/a | UK£5b |
Jun 30 2019 | n/a | n/a | UK£4b |
Mar 31 2019 | n/a | n/a | UK£4b |
Dec 31 2018 | UK£6m | UK£1m | UK£4b |
Sep 30 2018 | n/a | n/a | UK£2b |
Jun 30 2018 | n/a | n/a | UK£2b |
Mar 31 2018 | n/a | n/a | UK£1b |
Dec 31 2017 | UK£5m | UK£965k | UK£2b |
Compensation vs Market: Emma's total compensation ($USD15.93M) is above average for companies of similar size in the German market ($USD4.85M).
Compensation vs Earnings: Emma's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Emma Walmsley (55 yo)
7.7yrs
Tenure
UK£12,718,000
Compensation
Dame Emma N. Walmsley serves as an Independent Director of Microsoft Corp. since December 4, 2019. She serves as Chief Executive Officer of GlaxoSmithKline Plc since April 1, 2017. Dame Walmsley served as...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 7.7yrs | UK£12.72m | 0.040% € 26.0m | |
CFO & Executive Director | 1.7yrs | UK£5.14m | 0.0024% € 1.6m | |
Chief Digital & Technology Officer | 3.9yrs | no data | no data | |
Chief Scientific Officer and Head of R&D | 2.3yrs | no data | no data | |
SVP & Head of Investor Relations | no data | no data | no data | |
Senior VP & Group General Counsel of Legal & Compliance | 6.3yrs | no data | no data | |
Senior Vice President of Global Communications & CEO Office | 5.8yrs | no data | no data | |
President of Corporate Development | no data | no data | no data | |
Chief People Officer | 5.7yrs | no data | no data | |
President of Global Affairs | 7.7yrs | no data | 0.0057% € 3.8m | |
Chief Commercial Officer | 7.3yrs | no data | no data | |
Senior VP & Head of Worldwide Business Development for Pharmaceuticals Research Development | 6.5yrs | no data | no data |
6.0yrs
Average Tenure
55yo
Average Age
Experienced Management: GS71's management team is seasoned and experienced (6 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 7.9yrs | UK£12.72m | 0.040% € 26.0m | |
CFO & Executive Director | 1.6yrs | UK£5.14m | 0.0024% € 1.6m | |
Non-Executive Chairman | 5.3yrs | UK£765.00k | 0.0020% € 1.3m | |
Independent Non-Executive Director | 2.4yrs | UK£147.00k | 0.00040% € 262.8k | |
Non-Executive Director | 6.9yrs | UK£356.92k | 0.032% € 20.9m | |
Independent Non-Executive Director | 2.9yrs | UK£207.09k | 0.00017% € 111.7k | |
Independent Non-Executive Director | 3.6yrs | UK£174.93k | 0.00019% € 124.8k | |
Independent Non-Executive Director | 1.2yrs | UK£32.00k | 0.000060% € 39.4k | |
Senior Independent Non-Executive Director | 4.6yrs | UK£323.00k | 0.0015% € 1.0m | |
Independent Non-Executive Director | less than a year | no data | 0.000040% € 26.3k | |
Independent Non-Executive Director | 2.3yrs | UK£127.86k | 0.00011% € 72.3k | |
Independent Non-Executive Director | 8.9yrs | UK£173.36k | 0.00074% € 486.3k |
3.3yrs
Average Tenure
62yo
Average Age
Experienced Board: GS71's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/27 12:33 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GSK plc is covered by 62 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Kamla Singh | AlphaValue |
John Eade | Argus Research Company |
Odile Rundquist | Baader Helvea Equity Research |